Informational only — Not medical advice. Always consult a licensed healthcare provider.

Shasthya স্বাস্থ্য · Health, made simple
বাং
Community data Updated 23 hours ago

Salmeterol + Fluticasone Propionate

Long-acting selective β-adrenoceptor stimulants Prescription
Check interactions
🌐 বাংলায় দেখুন

Indications

Asthma

Salmeterol + Fluticasone Propionate is used for the regular treatment of asthma when a combination of a long-acting β2-agonist and an inhaled corticosteroid suits the patient. It is meant for two groups of patients. The first is patients whose asthma is not well controlled with an inhaled corticosteroid plus a short-acting inhaled β2-agonist taken 'as needed'. The second is patients whose asthma is already well controlled on both an inhaled corticosteroid and a long-acting β2-agonist.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Salmeterol Xinafoate is a selective, long-acting beta-2 agonist, used to treat asthma and other forms of diffuse airway obstruction. Fluticasone Propionate is a corticosteroid with mainly glucocorticoid activity. It is stated to act topically on the lungs, without systemic effects at the usual dose. Salmeterol protects against symptoms, while Fluticasone Propionate improves lung function and prevents exacerbations of the condition. So this combination can be a more convenient regime for patients who are already taking a β-agonist and an inhaled corticosteroid together.

Salmeterol is a selective, long-acting (12-hour) beta-2-adrenoceptor agonist. It has a long side chain that binds to the exo-site of the receptor.

Fluticasone Propionate, given by inhalation at recommended doses, has a potent glucocorticoid anti-inflammatory action within the lungs. This reduces symptoms and exacerbations of asthma, without the adverse effects seen when corticosteroids are given systemically.

Pregnancy & Breastfeeding

Pregnancy

This inhalation capsule should be considered during pregnancy only if the expected benefit to the mother is greater than any possible risk to the fetus. There isn't enough experience of salmeterol xinafoate and fluticasone propionate in human pregnancy. Animal studies of reproductive toxicity, with either medicine alone or both together, showed the fetal effects expected at excessive systemic exposure levels of a potent beta-2-adrenoreceptor agonist and glucocorticosteroid.

Lactation

For breast-feeding mothers, this inhalation capsule should be considered only if the expected benefit to the mother is greater than any possible risk to the child. There isn't enough experience of salmeterol xinafoate and fluticasone propionate in human lactation. After inhaled therapeutic doses, the plasma concentrations of salmeterol and fluticasone propionate are very low, so the concentrations in human breast milk are likely to be correspondingly low. Studies in lactating animals support this, as low concentrations were measured in the milk. There are no data available for human breast milk.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Salmeterol + Fluticasone Propionate inhaler, adults and adolescents 12 years and older: 2 puffs of 25 µg Salmeterol and 50 µg Fluticasone twice daily, or 2 puffs of 25 µg+125 µg twice daily, or 2 puffs of 25 µg+250 µg twice daily. Children (4 to 12 years) take 2 puffs of 25 µg+50 µg twice daily. For asthma, the inhalation capsule for adults and adolescents (12 years and older) is 50 µg+100 µg or 50 µg+250 µg twice daily, in the morning and evening, approximately 12 hours apart. The recommended starting dosages of 50 µg+100 µg and 50 µg+250 µg for patients aged 12 years and older are based on the patient's asthma severity. The maximum recommended dosage is 50 µg+500 µg twice daily. Pediatric patients (4 to 11 years) whose asthma is not controlled on an inhaled corticosteroid take 50 µg+100 µg twice daily, in the morning and evening, approximately 12 hours apart. For COPD, the inhalation capsule is 50 µg+250 µg twice daily, in the morning and evening, approximately 12 hours apart. Rinsing the mouth after each inhalation is advised. Special patient groups There's no need to adjust the dose in elderly patients or in those with renal impairment. No data are available on use of this medicine in patients with hepatic impairment. Using the inhaler The device is patient friendly, ready to use and easy to grip. Use it as per the instructions for use.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.